U.S. Department of Health and Human Services
Saul Malozowski
 

 Contact Info

 
Tel: 301-451-4683
Email: sm007@nih.gov
 

 Select Experience

 
  • Senior Advisor for Clinical Trials and Diabetes TranslationDEM, NIDDK, NIH2001-2005
  • Medical Team LeaderDivision of Endocrine and Metabolic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration1998-2001
  • Visiting FellowDevelopmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health1983-1986
  • Chief ResidentPediatric Endocrinology, Children's General Hospital, Dr. Ricardo Gutierrez, Buenos Aires1982-1983
  • Fellow in Pediatric EndocrinologyChildren's General Hospital, Dr. Ricardo Gutierrez, Buenos Aires1980-1982
  • Pediatric ResidentChildren's General Hospital, Dr. Ricardo Gutierrez, Buenos Aires1978-1980
  • M.B.A.The George Washington University School of Business and Public Management1996-1998
  • Ph.D.University of Buenos Aires School of Medicine, Argentina1990
  • M.D.University of Buenos Aires School of Medicine, Argentina1976

Saul Malozowski, M.D., Ph.D., M.B.A.

Program Director, Division of Diabetes, Endocrinology, and Metabolic Diseases

Current Responsibilities & Activities

In my position as program director for the Endocrinology and Physiology Program, I coordinate scientific portfolios for bone research, neuroendocrinology, and clinical endocrinology.  The bone program encompasses basic and clinical research on the hormonal regulation of bone and mineral metabolism in health and disease, endocrine aspects of disorders affecting bone, all facets of parathyroid disorders, the effects of systemic or local-acting hormones and their receptors on bone metabolism, bone-active cytokines, studies of calcium-related processes, basic and clinical studies of vitamin D, bone morphogenesis, and studies addressing the impact of metabolic derangements in Type 1 and Type 2 diabetes mellitus on the skeleton.

My other research interests lie within studies surrounding neuroendocrinology that examine a range of topics, including the physiological response to stress through the hypothalamic-pituitary-adrenal axis, neuropeptides and their signaling pathways, gene regulation in the hypothalamus and pituitary gland, diseases of the pituitary, pituitary hormone receptors and actions on target tissues, and neuroendocrine-immune interactions.

My work for the Division of Diabetes, Endocrinology, and Metabolic Diseases also includes evaluation of human subject protection for all clinical research.  I am also a member of the Trans NIH research group that addresses various topics on bone health.  I represent the NIDDK on the ACCORDION (the longitudinal follow-up study of patients previously involved in the Action to Control Cardiovascular Risk in Diabetes Trial) Study, which is led by the National Heart, Lung, and Blood Institute.  Finally, I am the program officer of The Vitamin D and Type 2 Diabetes Study (D2d study), a randomized multicenter placebo-controlled study assessing the safety and efficacy of vitamin D to prevent or delay the development of type 2 diabetes in subjects at risk.

​Research Programs

Diabetes: Treatment, Prevention, and Complications
This program supports both basic and clinical studies aimed at addressing the prevention, treatment, and pathophysiology of type 1 and type 2 diabetes

Endocrinology and Hormone Signaling
The Endocrinology and Hormone Signaling program supports basic and clinical research on neuroendocrinology, the HPA axis, bone metabolism, mechanisms of nuclear receptor signaling, and signaling pathways involved in nutrient sensing at target tissues

Current Committee Memberships

  • NIH Obesity Research Task ForceMember
  • Trans-HHS Bone Health Initiatives CommitteeMember
  • Trans-NIH Endocrine Working GroupMember
  • NDEP Children’s Working GroupMember
  • ACCORDIONNIDDK Representative
  • Vitamin D for Bone Working GroupNIDDK Representative